All Stories

  1. Genotype‐driven asthma prescribing of inhaled corticosteroids and long‐acting β2‐agonist: A cost‐effectiveness analysis

    Article • Pediatric Pulmonology, April 2024, Wiley

    Professor ANDRES F ZULUAGA

  2. Is there an association between TLR 4 Asp 299Gly and severe RSV infection? Systematic review and metanalysis

    Article • Pediatric Pulmonology, April 2024, Wiley

    Professor ANDRES F ZULUAGA

  3. Continuous positive airway pressure in children under 6 years with severe acute lower respiratory infections: Systematic review and metanalysis

    Article • Pediatric Pulmonology, March 2024, Wiley

    Professor ANDRES F ZULUAGA

  4. Opioides en uci pediátrica y neonatal: propuesta para su desmonte

    Article • IATREIA, February 2024, Universidad de Antioquia

    Professor ANDRES F ZULUAGA

  5. Respuesta sobre la bioequivalencia en los medicamentos bioterapeúticos

    Article • Acta neurológica colombiana, January 2024, Asociacion Colombiana de Neurologia

    Professor ANDRES F ZULUAGA

  6. Cost-effectiveness of linezolid to ventilator-associated pneumonia in Colombia

    Article • BMC Infectious Diseases, January 2024, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  7. Economic Evidence Supports the Cost Savings of Sputum Eosinophil Counts to guide the treatment of pediatrics patients with Persistent Asthma: Implications for Clinical Practice Guidelines in Middle-Income Countries.

    Article • Journal of Asthma, December 2023, Taylor & Francis

    Professor ANDRES F ZULUAGA

  8. Assessing the economic implications of impulse oscillometry in preschoolers with asthma in Colombia

    Article • Pediatric Pulmonology, December 2023, Wiley

    Professor ANDRES F ZULUAGA

  9. Cost effectiveness of omalizumab for severe asthma in Colombia

    Article • Journal of Asthma, October 2023, Taylor & Francis

    Professor ANDRES F ZULUAGA

  10. Medicamentos bioterapéuticos: uso de toxinas botulínicas en la era de biosimilares

    Article • Acta neurológica colombiana, June 2023, Asociacion Colombiana de Neurologia

    Professor ANDRES F ZULUAGA

  11. Vasoplejía y edema pulmonar en sobredosis mixta de antihipertensivos, reporte de caso

    Article • IATREIA, May 2023, Universidad de Antioquia

    Professor ANDRES F ZULUAGA

  12. Pharmacokinetic/Pharmacodynamic Index Linked to In Vivo Efficacy of the Ampicillin-Ceftriaxone Combination against Enterococcus faecalis

    Article • Antimicrobial Agents and Chemotherapy, January 2023, ASM Journals

    Professor ANDRES F ZULUAGA

  13. A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization

    Article • Journal of Pharmacokinetics and Pharmacodynamics, December 2022, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  14. Reacción similar a la enfermedad del suero secundaria al uso de cefalotina: reporte de un caso

    Article • Infectio, August 2022, Asociacion Colombiana de Infectologia - ACIN

    Professor ANDRES F ZULUAGA

  15. Validación de una nueva estrategia para la identificación de variantes de SARS-CoV-2 mediante secuenciación del gen Espiga por Sanger

    Article • Enfermedades Infecciosas y Microbiología Clínica, May 2022, Elsevier

    Professor ANDRES F ZULUAGA

  16. Population Pharmacokinetic Models of Antituberculosis Drugs in Patients: A Systematic Critical Review

    Article • Therapeutic Drug Monitoring, February 2021, Wolters Kluwer Health

    Professor ANDRES F ZULUAGA

  17. Validación de una técnica de PCR dúplex usando el gen E y RNasa P para el diagnóstico de SARS-CoV-2

    Article • Enfermedades Infecciosas y Microbiología Clínica, January 2021, Elsevier

    Professor ANDRES F ZULUAGA

  18. A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone

    Article • PLoS ONE, December 2020, PLOS

    Professor ANDRES F ZULUAGA

  19. Use of low-molecular-weight heparin in severe paraquat poisoning: a case report

    Article • Journal of Medical Case Reports, December 2020, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  20. Social and economic variables related with Paraquat self-poisoning: an ecological study

    Article • BMC Public Health, March 2020, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  21. A counterfeit multivitamin product inducing severe bleeding disorders in humans

    Article • Clinical Toxicology, January 2020, Taylor & Francis

    Professor ANDRES F ZULUAGA

  22. The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease

    Article • American Journal of Hematology, December 2019, Wiley

    Professor ANDRES F ZULUAGA

  23. Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis

    Article • Therapeutic Drug Monitoring, December 2019, Wolters Kluwer Health

    Professor ANDRES F ZULUAGA

  24. Eficacia de las combinaciones antimicrobianas para el tratamiento de infecciones enterocócicas: una revisión crítica

    Article • Revista chilena de infectología, October 2019, SciELO Comision Nacional de Investigacion Cientifica Y Tecnologica (CONICYT)

    Professor ANDRES F ZULUAGA

  25. Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage

    Article • BMC Research Notes, September 2019, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  26. Artralgia inducida por levofloxacina: Reporte de un caso

    Article • Infectio, September 2019, Asociacion Colombiana de Infectologia - ACIN

    Professor ANDRES F ZULUAGA

  27. Epidemiología de los envenenamientos por animales acuáticos reportados a un centro de control toxicológico colombiano

    Article • Revista de Salud Pública, July 2019, Universidad Nacional de Colombia

    Professor ANDRES F ZULUAGA

  28. Toxicity induced by multiple high doses of vitamin B12 during pernicious anemia treatment: a case report

    Article • Clinical Toxicology, April 2019, Taylor & Francis

    Professor ANDRES F ZULUAGA

  29. Prediction of Ligands Binding Acetylcholinesterase with Potential Antidotal Activity: A Virtual Screening Approach

    Article • Molecular Informatics, April 2019, Wiley

    Professor ANDRES F ZULUAGA

  30. Burden of paraquat poisoning in the department of Antioquia, Colombia

    Article • BMC Pharmacology and Toxicology, February 2019, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  31. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin

    Article • PLoS ONE, February 2019, PLOS

    Professor ANDRES F ZULUAGA, Dr Omar Vesga

  32. Mioclonías inducidas por salbutamol

    Article • Biomédica, September 2018, Instituto Nacional de Salud

    Professor ANDRES F ZULUAGA

  33. CIEMTO: the new drug and poison research and information center in Medellín, Colombia

    Article • Journal of Toxicology Clinical Toxicology, April 2017, Taylor & Francis

    Professor ANDRES F ZULUAGA

  34. Immunomodulatory activity of itraconazole in lung

    Article • Tropical Journal of Pharmaceutical Research, January 2017, African Journals Online (AJOL)

    Professor ANDRES F ZULUAGA

  35. Modeling and simulation of ciprofloxacin pharmacokinetics: electric circuits approach

    Article • January 2017, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  36. Potential clinical application of surface electromyography as indicator of neuromuscular recovery during weaning tests after organophosphate poisoning

    Article • Revista Brasileira de Terapia Intensiva, January 2017, GN1 Genesis Network

    Professor ANDRES F ZULUAGA

  37. Antifungal pharmacodynamics: Latin America's perspective

    Article • The Brazilian Journal of Infectious Diseases, November 2016, Elsevier

    Professor ANDRES F ZULUAGA

  38. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products

    Article • International Journal of Antimicrobial Agents, November 2016, Elsevier

    Professor ANDRES F ZULUAGA

  39. Dependence to legally prescribed opioid analgesics in a university hospital in Medellin-Colombia: an observational study

    Article • BMC Pharmacology and Toxicology, September 2016, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  40. Perspectives for the structure-based design of acetylcholinesterase reactivators

    Article • Journal of Molecular Graphics and Modelling, July 2016, Elsevier

    Professor ANDRES F ZULUAGA

  41. Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam

    Article • PLoS ONE, May 2016, PLOS

    Professor ANDRES F ZULUAGA

  42. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis

    Article • PLoS ONE, November 2015, PLOS

    Professor ANDRES F ZULUAGA

  43. Pharmacodynamics of nine generic products of amikacin compared with the innovator in the neutropenic mouse thigh infection model

    Article • BMC Research Notes, October 2015, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  44. A strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic mice

    Article • Journal of Biomedical Science, March 2015, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  45. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam

    Article • International Journal of Antimicrobial Agents, February 2015, Elsevier

    Professor ANDRES F ZULUAGA

  46. An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics

    Article • Antimicrobial Agents and Chemotherapy, October 2014, ASM Journals

    Professor ANDRES F ZULUAGA, Professor ANDRES F ZULUAGA

  47. Impact on Resistance of the Use of Therapeutically Equivalent Generics: the Case of Ciprofloxacin

    Article • Antimicrobial Agents and Chemotherapy, October 2014, ASM Journals

    Professor ANDRES F ZULUAGA, Dr Omar Vesga

  48. Una percepción en médicos bogotanos acerca del riesgo de reacciones adversas a grupos de medicamentos de uso común

    Article • Biomédica, May 2014, Instituto Nacional de Salud

    Professor ANDRES F ZULUAGA

  49. About the Validation of Animal Models to Study the Pharmacodynamics of Generic Antimicrobials

    Article • Clinical Infectious Diseases, April 2014, Oxford University Press (OUP)

    Professor ANDRES F ZULUAGA

  50. Uso del Registro de Solicitudes de Medicamentos no Incluidos en el Listado de Medicamentos Esenciales como Nueva Fuente de Información en los Sistemas Nacionales de Farmacovigilancia

    Article • Value in Health Regional Issues, December 2013, Elsevier

    Professor ANDRES F ZULUAGA

  51. Generic Vancomycin Enriches Resistant Subpopulations of Staphylococcus aureus after Exposure in a Neutropenic Mouse Thigh Infection Model

    Article • Antimicrobial Agents and Chemotherapy, November 2011, ASM Journals

    Professor ANDRES F ZULUAGA

  52. Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator

    Article • Antimicrobial Agents and Chemotherapy, June 2010, ASM Journals

    Professor ANDRES F ZULUAGA

  53. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin

    Article • BMC Infectious Diseases, June 2010, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  54. Determination of Therapeutic Equivalence of Generic Products of Gentamicin in the Neutropenic Mouse Thigh Infection Model

    Article • PLoS ONE, May 2010, PLOS

    Professor ANDRES F ZULUAGA

  55. Potential therapeutic failure of generic vancomycin in a liver transplant patient with MRSA peritonitis and bacteremia

    Article • Journal of Infection, October 2009, Elsevier

    Professor ANDRES F ZULUAGA

  56. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics

    Article • BMC Clinical Pharmacology, January 2009, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  57. Etiologic Diagnosis of Chronic Osteomyelitis

    Article • Archives of Internal Medicine, January 2006, American Medical Association (AMA)

    Professor ANDRES F ZULUAGA

  58. Article • BMC Infectious Diseases, January 2006, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  59. Article • BMC Microbiology, January 2005, Springer Science + Business Media

    Professor ANDRES F ZULUAGA

  60. Article • BMC Infectious Diseases, January 2002, Springer Science + Business Media

    Professor ANDRES F ZULUAGA